Health Products

MULTI-PROGRAM NEUROSTIMULATORS AND ACCESSORIES (2015-07-22)

· Published by Health Canada · Official notice

Details

Alert type: Medical Device Recall
Category: Medical Device
Issue: Medical Devices
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type II
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Lot or serial numberCompaniesBrand nameModel or catalog number
All lots
Manufacturer
Medtronic Inc.
710 Medtronic Parkway NE
Minneapolis
Minnesota
UNITED STATES
D. SOLETRA QUADRIPOLAR MULTI-PROGRAMMABLE NEUROSTIMULATOR7426
All lots
Manufacturer
Medtronic Inc.
710 Medtronic Parkway NE
Minneapolis
Minnesota
UNITED STATES
E. ACTIVA SC - NEUROSTIMULATOR37602
All lots
Manufacturer
Medtronic Inc.
710 Medtronic Parkway NE
Minneapolis
Minnesota
UNITED STATES
B. ACTIVA PC INS - MULTI-PROGRAM NEUROSTIMULATOR37601
All lots
Manufacturer
Medtronic Inc.
710 Medtronic Parkway NE
Minneapolis
Minnesota
UNITED STATES
C. ACTIVA RC MULTI-PROGRAM RECHARGEABLE NEUROSTIMULATOR37612
All lots
Manufacturer
Medtronic Inc.
710 Medtronic Parkway NE
Minneapolis
Minnesota
UNITED STATES
A. KINETRA NEUROSTIMULATOR PULSE GENERATOR & ACCESSORY KIT7428

Introduction

Affected Products

A. KINETRA NEUROSTIMULATOR PULSE GENERATOR & ACCESSORY KIT

B. ACTIVA PC INS - MULTI-PROGRAM NEUROSTIMULATOR

C. ACTIVA RC MULTI-PROGRAM RECHARGEABLE NEUROSTIMULATOR

D. SOLETRA QUADRIPOLAR MULTI-PROGRAMMABLE NEUROSTIMULATOR

E. ACTIVA SC - NEUROSTIMULATOR

Reason

The purpose of this notification is to notify implanting and follow up physician of information that is being added to the warnings and adverse events sections of Medtronic’s deep brain stimulation (DBS) labeling. These labeling updates result from Medtronic’s ongoing monitoring of reported events, clinical trials and published literature. The labeling updates further clarify potential risks which have been reported with DBS therapy. Medtronic is sharing this information with physicians to help with management of current patients treated with DBS therapy. Additional warnings being added to the labeling: DBS therapy for dystonia: status Dystonicus - severe, life-threatening dystonia symptoms, including status Dystonicus (also known as dystonic crisis or dystonic storm), during ongoing or loss of DBS therapy may result in respiratory compromise and Rhabdomyolysis. In rare cases, Rhabdomyolysis may progress to multi-organ failure and death. Monitor patients receiving DBS therapy for these symptoms. Emphasize the importance of contacting the patient's physician if they experience increased severity of symptoms. DBS therapy for epilepsy: return of symptoms - cessation or reduction of stimulation may potentially lead to an increase in seizure frequency or severity. Symptoms may return with intensity greater than was experienced prior to system implant, including the potential for status epilepticus. Emphasize the importance of contacting the patient's physician if they experience worsening of seizure frequency or severity.it is also important that the patient or caregiver knows how to use the patient programmer in case the Neurostimulator is accidentally turned off. Additional adverse events being added to the labeling for all indications of DBS therapy: meningitis, encephalitis, or brain abscess resulting from infection involving the brain and/or central nervous system. Focal edema localized to the area around the lead immediate or delayed intracranial hemorrhage or cerebral infarction which could be symptomatic, or which could result in temporary or permanent neurological injury or death aseptic Intraparenchymal cyst formation around the distal lead tip
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime